Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Barbara Pro, MD, Jonathan E. Brammer, MD, Carla Casulo, MD, Eric Jacobsen, MD, Monica Mead, MD BS, Neha Mehta-Shah, MD, Jasmine M. Zain, MD, Pier Luigi Zinzani, MD, Stephanie Lustgarten, PhD, Hagop Youssoufian, MD, Steven M. Horwitz, MD

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-140412

Published: 2020

Journal Articles

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

Jennifer R Brown, MD PhD, Kam Sprott, PhD, Santosh Reddy, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4312.

https://doi.org/10.1182/blood-2019-122491

Published: 2019

Journal Articles

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Reem Karmali, MD, Hagop Youssoufian, MD, Kam Sprott, PhD, David T. Weaver, PhD, Narayana Narasimhan, Stephanie Lustgarten, PhD, Gloria Patrick, Alena Zalutskaya, Leo I. Gordon, MD

Blood (2019) 134 (Supplement_1): 5251.

https://doi.org/10.1182/blood-2019-124406

Published: 2019

Journal Articles

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Pier Luigi Zinzani, MD, Ian W. Flinn, MD PhD, Carole B. Miller, MD, Scott A. Tetreault, MD, Kirit M. Ardeshna, MBBChir, NgocDiep Le, MD PhD, Jonathan A. Pachter, PhD, Kam Sprott, PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Nina D. Wagner-Johnston, MD

Blood (2018) 132 (Supplement 1): 4167.

https://doi.org/10.1182/blood-2018-99-117903

Published: 2018

Journal Articles

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Ian W. Flinn, MD PhD, Marco Montillo, MD, Zsolt Nagy, MD PhD, Zoltán Gasztonyi, MD, Matthew S. Davids, MD, Klaus Geissler, MD, Jose J. Rifon Roca, MD, Leanne Berkhan, ADHB, Fritz Offner, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Julio Delgado, MD

Blood (2018) 132 (Supplement 1): 3146.

https://doi.org/10.1182/blood-2018-99-120027

Published: 2018

Journal Articles

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

Jennifer R. Brown, MD PhD, Ian W. Flinn, MD PhD, Matthew S. Davids, MD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, Zsolt Nagy, MD PhD, Julio Delgado, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Ulrich Jaeger, MD, Paolo Ghia, MD PhD, Stephan Stilgenbauer, Carol Moreno, MD PhD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, Kam Sprott, PhD, Jonathan A. Pachter, PhD, David T. Weaver, PhD, Florence Cymbalista, MD PhD

Blood (2018) 132 (Supplement 1): 1856.

https://doi.org/10.1182/blood-2018-99-114251

Published: 2018

Journal Articles

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Matthew S. Davids, MD, Bryone J. Kuss, PhD BMBS, FRCPA, FRACP, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Marco Montillo, MD, James Essell, MD, Nicole Lamanna, MD, Zsolt Nagy, MD PhD, Constantine S. Tam, MBBS (Hons), MD FRACP, FRCPA, Stephan Stilgenbauer, Paolo Ghia, MD PhD, Julio Delgado, MD, NgocDiep Le, MD PhD, Stephanie Lustgarten, PhD, David T. Weaver, PhD, Ulrich Jaeger, MD

Blood (2018) 132 (Supplement 1): 3140.

https://doi.org/10.1182/blood-2018-99-117521

Published: 2018

Journal Articles

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Blood (2018) 132 (4): 393–404.

https://doi.org/10.1182/blood-2016-09-739086

Published: 2018

Includes: Supplemental data

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Justin R. Pritchard, PhD, Michael W. Schmitt, MD PhD, J. Graeme Hodgson, PhD, Stephanie Lustgarten, PhD, Shijie Tang, PhD, Lawrence A. Loeb, MD PhD, Jerald P. Radich, MD, Victor M. Rivera, PhD

Blood (2016) 128 (22): 1061.

https://doi.org/10.1182/blood.V128.22.1061.1061

Published: 2016

Journal Articles

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Hui Huang, PhD MBA

Blood (2016) 128 (22): 3081.

https://doi.org/10.1182/blood.V128.22.3081.3081

Published: 2016

Journal Articles

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Michael J. Mauro, MD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Neil P. Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Victor M. Rivera, PhD, Stephanie Lustgarten, PhD, Sergio Santillana, MD, Michael C. Heinrich, Brian J. Druker, MD, Michael W. Deininger, MD PhD, Moshe Talpaz, MD

Blood (2016) 128 (22): 3063.

https://doi.org/10.1182/blood.V128.22.3063.3063

Published: 2016

Journal Articles

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

Elias J. Jabbour, MD, Jorge E. Cortes, MD, Moshe Talpaz, MD, Michele Baccarani, MD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Francois Guilhot, MD, Michael W. Deininger, MD PhD, Neil Shah, MD PhD, Dale L. Bixby, MD, Ian W. Flinn, MD PhD, Thomas O'Hare, PhD, Stephanie Lustgarten, PhD, Victor M. Rivera, PhD, Sergio Santillana, MD, Hagop M. Kantarjian, MD

Blood (2016) 128 (22): 3067.

https://doi.org/10.1182/blood.V128.22.3067.3067

Published: 2016

Journal Articles

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Wendy T. Parker, David T. O. Yeung, Alexandra L. Yeoman, Haley K. Altamura, Bronte A. Jamison, Chani R. Field, J. Graeme Hodgson, Stephanie Lustgarten, Victor M. Rivera, Timothy P. Hughes, Susan Branford

Blood (2016) 127 (15): 1870–1880.

https://doi.org/10.1182/blood-2015-09-666214

Published: 2016

Includes: Supplemental data

Journal Articles

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood (2016) 127 (6): 703–712.

https://doi.org/10.1182/blood-2015-08-660977

Published: 2016

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Blood (2015) 126 (23): 4025.

https://doi.org/10.1182/blood.V126.23.4025.4025

Published: 2015

Journal Articles

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Moshe Yair Levy, MD, Lisa J. McGarry, MPH, Stephanie Lustgarten, PhD, Mo Yang, PhD, Frank G. Haluska, MD

Blood (2015) 126 (23): 1588.

https://doi.org/10.1182/blood.V126.23.1588.1588

Published: 2015

Journal Articles

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

Michael J. Mauro, MD, Lisa J. McGarry, MPH, Mo Yang, PhD, Stephanie Lustgarten, PhD, Hui Huang, MBA, PhD

Blood (2015) 126 (23): 1591.

https://doi.org/10.1182/blood.V126.23.1591.1591

Published: 2015

Journal Articles

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Blood (2015) 126 (23): 5142.

https://doi.org/10.1182/blood.V126.23.5142.5142

Published: 2015

NARROW

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results

Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial

A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)

Prognostic and Immune-Related Factors for Response to Duvelisib in the Phase 2 DYNAMO TM Clinical Trial in iNHL

Characterization of the Long-Term Efficacy and Safety of Duvelisib Monotherapy in Patients with Relapsed/Refractory CLL/SLL on Treatment for > 2 Years across 4 Clinical Studies

Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUO TM Study

The Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL: Updated Results from the DUO Crossover Extension Study

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Analysis of the Sub-Clonal Origins of Compound Mutations in Patients with Refractory Ph+ Malignancies Treated with Ponatinib

Predictors of Ponatinib Therapy Duration Among Real-World Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients in the US

Ponatinib in Chronic-Phase Chronic Myeloid Leukemia Patients: Final Report from a Phase 1 Trial

Long-Term Follow-up of the Efficacy and Safety of Ponatinib in Philadelphia Chromosome-Positive Leukemia Patients with the T315I Mutation

The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Efficacy and Safety of Ponatinib in CP-CML Patients By Number of Prior Tyrosine Kinase Inhibitors: 4-Year Follow-up of the Phase 2 PACE Trial

Relationship of Line of Therapy to Efficacy for Ponatinib in 3rd-Line Versus 4th-Line Chronic-Phase Chronic Myeloid Leukemia (CML)

Real-World Ponatinib Prescribing Patterns and Outcomes in US Patients

Evaluation of the Benefit/Risk Profile of Ponatinib in CP-CML Patients over Time: 4-Year Follow-up of the Phase 2 PACE Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only